https://www.industryreportermassachusetts.com/article/943133258-xenon-announces-azetukalner-nda-submission-to-fda-for-focal-seizures-and-provides-update-on-psychiatry-clinical-program
Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on...
Industry Reporter: Massachusetts is an online news publication focusing on industries in the Massachusetts: The latest industries and services news from...
focal seizuresxenonannouncesazetukalnernda
https://ctv.veeva.com/study/a-randomized-study-of-azetukalner-versus-placebo-in-depressive-episodes-associated-with-bipolar-i-or?comeFrom=%7B%22type%22%3A%22site%22%2C%22slug%22%3A%22delricht-research-priority-care-charlotte-nc%22%7D
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I...
X-CEED is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of azetukalner in adult participants...
randomized studyassociated withazetukalnerversusplacebo